MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension

• MannKind Corporation (NASDAQ: MNKD) and United Therapeutics Corporation (NASDAQ: UTHR) have announced that the FDA has accepted for review the marketing application of Tyvaso DPI (inhaled treprostinil).

• Under priority review status, the application seeks approval to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

• The agency's review will complete in October and indicated that they had not identified any potential review issues at this time.

• Tyvaso DPI is a next-generation dry powder formulation of Tyvaso. If approved, Tyvaso DPI is expected to provide a more convenient method of administration as compared with traditional nebulized Tyvaso therapy.

• Price Action: MNKD shares are up 11% at $4.55 during the premarket session on the last check Wednesday, while UTHR closed at $178.45 on Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of M Issued At 26% Discount

• RAPT Therapeutics Raises 5M Via Equity At 6% Discount

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.